Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com

Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

By Jared Kaltwasser

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

By Giuliana Grossi

June 12th 2025

AJMC

Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

By Brigham Walker, PhD
Lalan Wilfong, MD

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com

C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

By Jared Kaltwasser

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

March 8th 2017

A Self-Persuasion App to Boost Adolescent HPV Vaccination Among Low-Income Families

Surabhi Dangi-Garimella, PhD

A pilot study conducted at a safety net hospital has armed researchers with a new educational tool: a digital app to persuade parents to vaccinate their adolescent against the human papilloma virus (HPV).

March 7th 2017

Study Compares Cost-Effectiveness of Immune Checkpoint Inhibitors in Advanced Melanoma

First-line pembrolizumab every 3 weeks followed by second-line ipilimumab, and first-line nivolumab followed by second-line ipilimumab are cost-effective strategies in patients with advanced melanoma expressing wild-type BRAF.

March 7th 2017

Walgreens Trains Staff, Identifies Cancer-Specialized Pharmacies

Surabhi Dangi-Garimella, PhD

Pharmacists and pharmacy technicians working at 50 specialty pharmacy locations owned by Walgreens have completed a cancer-focused curriculum of advanced education courses.

March 6th 2017

Remuneration for Gene Therapy Treatments: ICER Provides Early Recommendations

Surabhi Dangi-Garimella, PhD

How will drug developers price gene therapy treatments to recover their investment and ensure that society can bear the impending cost?

March 6th 2017

Part D Subsidies Can Help Reduce Racial Disparities in Breast Cancer Treatment Persistence

Christina Mattina

A recent study has found that low-income subsidies under the Medicare Part D program can help improve rates of persistence and adherence to breast cancer therapies among Hispanic and black women.

March 6th 2017

The Oncology Care Model: What to Expect in the First Data Feed

Eight months into the Oncology Care Model, find out what participants can expect from the first performance data feed released later this month.

March 5th 2017

Dana-Farber Clinical Pathways Saved Costs, Maintained Outcomes in NSCLC

Surabhi Dangi-Garimella, PhD

Implementation of clinical pathways saved $15,013 in the total cost of care per patient over a year.

Kim Eason Discusses How Payers Can Collaborate With Oncology Providers

March 5th 2017

Kim Eason Discusses How Payers Can Collaborate With Oncology Providers

Insurers can engage the practices they work with by building a sense of trust and open communication with the providers, according to Kim Eason, manager at Horizon Blue Cross Blue Shield of NJ.

March 4th 2017

New Clinical Pathways Program Seamlessly Integrates Into Physician Workflow

A new clinical pathways program at the Cancer Treatment Centers of America will help inform treatment by seamlessly integrating into the physician’s electronic health record.

Melissa Thompson on Preparing Patients for the Reality of Cancer Treatment

March 3rd 2017

Melissa Thompson on Preparing Patients for the Reality of Cancer Treatment

Hospitals don't always adequately prepare patients for the reality of cancer treatment and all the ways it might affect someone's life, explained Melissa Thompson, MBA, healthcare strategist, patient, and self-advocate.

This Week in Managed Care: March 3, 2017

March 3rd 2017

This Week in Managed Care: March 3, 2017

This week, the top news in managed care included President Donald Trump's first address to Congress, which included guiding principles for replacing the Affordable Care Act, a leaked version of the House GOP's own draft for healthcare reform, and a study finds a concerning trend in colorectal cancer rates among young adults.

March 2nd 2017

Insurance Status, Race, and Education Remain Persistent Barriers to Cancer Screening

Surabhi Dangi-Garimella, PhD

While colorectal cancer screening rates have seen a recent progress toward achieving the Healthy People 2020 objectives, breast cancer screening rates have remained static, and cervical cancer screening rates have been declining.

March 2nd 2017

Juno's ROCKET Trial, Evaluating CAR-T Treatment in Leukemia Patients, Shelved

Surabhi Dangi-Garimella, PhD

The company did not recover from the 5 patient deaths associated with JCAR015 in 2016.

Impact of a Value-Based Formulary in Three Chronic Disease Cohorts

March 1st 2017

Impact of a Value-Based Formulary in Three Chronic Disease Cohorts

Research presented by Kai Yeung, PharmD, PhD, scientific investigator I, Group Health Research Institute, at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Marcia Baker: Reducing Barriers to Medication Access and Adherence

March 1st 2017

Marcia Baker: Reducing Barriers to Medication Access and Adherence

Presentation by Marcia Baker, MS, Ed, director, Corporate Development & Programs, Mended Hearts, Inc, the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed CareÃ‚Â®.

Fred Hutchinson Cancer Research Center: Financial Literacy for Cancer Patients

March 1st 2017

Fred Hutchinson Cancer Research Center: Financial Literacy for Cancer Patients

Work presented by Veena Shankaran, MD, MS, associate professor, Division of Medical Oncology, University of Washington and associate member, Clinical Research Division, Fred Hutchinson Cancer Research Center, at the the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed CareÃ‚Â®.

March 1st 2017

Addressing Patient Needs Around the Cost of Care

Surabhi Dangi-Garimella, PhD

A key takeaway from a panel discussion at the Patient Access Network Foundation’s second cost-sharing roundtable was the need for educating stakeholders.

March 1st 2017

Concerning Trends in Colorectal Cancer Incidence Among Younger Adults

Christina Mattina

The incidence of colorectal cancer continues to decline for older Americans, but researchers have noticed a significant uptick in prevalence among young adults.

Barry Russo on How Education Can Help Practices Achieve OCM Implementation

March 1st 2017

Barry Russo on How Education Can Help Practices Achieve OCM Implementation

The Oncology Care Model (OCM) can challenge providers who are overwhelmed by the wide scope of data involved, according to Barry Russo, CEO of The Center for Cancer & Blood Disorders. He explained the importance of educating staff, physicians, and patients to help ease the journey towards any new model.

March 1st 2017

Kite Pharma Reports Positive Data From ZUMA-1, Evaluating a CAR-T Treatment

Median overall survival was not yet reached at a median follow-up of 8.7 months on the company’s ZUMA-1 trial.

February 28th 2017

Smilow's In-House Pharmacy Saved Costs, Beneficial to Patients

Surabhi Dangi-Garimella, PhD

Expanding a health system pharmacy’s operations to include specialty drugs, namely oral oncology agents, improved patient care by reducing errors and saving costs.

February 27th 2017

NCI-Funded Study Hopes to Unveil Disparity Among African American Cancer Survivors

Surabhi Dangi-Garimella, PhD

A new grant aims to gather data on thousands of African American cancer survivors to understand factors that influence disease progression, recurrence, mortality, and quality of life.

February 27th 2017

Proposed Colorectal Cancer Screening Initiatives Vary in Cost-Effectiveness

Christina Mattina

A recent cost-effectiveness analysis of 4 colorectal cancer screening initiatives found that some strategies may be more valuable than others in reducing screening disparities.

Jonathan Hirsch: Precision Medicine Is the Future of Value-Based Cancer Care

February 26th 2017

Jonathan Hirsch: Precision Medicine Is the Future of Value-Based Cancer Care

Precision medicine has demonstrated clinical utility and cost-effectiveness, which is why many believe this approach will be key to value-based cancer care in the future, said Jonathan Hirsch, founder and president of Syapse.

February 24th 2017

Personalizing Cancer Treatment Based on Muscle Mass to Reduce Toxicity

Surabhi Dangi-Garimella, PhD

Using body composition metrics to guide the dose in patients receiving anthracyclines-taxane—based chemotherapy for breast cancer can reduce treatment-related toxicity.

Podcast: Takeaways From the 5th Annual Patient-Centered Oncology Care Meeting

February 23rd 2017

Podcast: Takeaways From the 5th Annual Patient-Centered Oncology Care Meeting

Presenters and panelists at the 5th annual Patient-Centered Oncology Care meeting provide their key takeaways.

February 23rd 2017

Lenalidomide Approved as Maintenance for Multiple Myeloma Following Transplant

The FDA has approved lenalidomide as maintenance therapy in patients with multiple myeloma following autologous stem cell transplant.

Dr Joseph Alvarnas Discusses Awareness of Cancer Patients' Financial Concerns

February 23rd 2017

Dr Joseph Alvarnas Discusses Awareness of Cancer Patients' Financial Concerns

Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology, admits that he was once “oblivious” to his patients’ concerns about the cost of cancer treatment. However, it is important for clinicians to empathize with these fears and understand how they can factor into a patient’s care choices.

February 23rd 2017

AJMC®'s Evidence-Based Oncologyâ„¢ Publishes Third Annual Immuno-Oncology Issue

The advance of CAR-T technology and the rise of immuno-oncology alongside emerging new payment models highlight the annual review in Evidence-Based Oncologyâ„¢, which looks at how researchers are harnessing the immune system to bring unprecedented results in cancer care.

February 22nd 2017

Bundled Payments and Other Cost-Management Approaches to Oncology Care

Christina Mattina

At the 5th annual Patient-Centered Oncology CareÂ® meeting, stakeholders shared their views on how bundled payments, clinical pathways, and other value-based approaches can be implemented in cancer care while ensuring adequate care quality.

...

80 81 82 83 84 85 86 87 88

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions